Update: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment

https://www.youtube.com/watch?v=4MJMl1HeQIE

The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. 

“These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.”

— Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. 

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

• In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median Progression Free Survival (PFS) to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 

• NETTER-2 is the first and only positive Phase III trial for a radioligand therapy (RLT) or PRRT in the first-line setting, demonstrating the potential of RLTs in earlier treatment lines.

• Novartis is investigating a broad portfolio of RLTs or PRRT in advanced cancers, in addition to GEP-NETs, including lung, prostate, breast, colon, glioblastoma and pancreatic cancers to continue reimagining medicine for patients.

Read the full Novartis Press Release:

https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors